Investigational Drug Information for JNJ-56136379
✉ Email this page to a colleague
What is the drug development status for JNJ-56136379?
JNJ-56136379 is an investigational drug.
There have been 15 clinical trials for JNJ-56136379.
The most recent clinical trial was a Phase 2 trial, which was initiated on August 1st 2019.
The most common disease conditions in clinical trials are Hepatitis B, Hepatitis A, and Hepatitis. The leading clinical trial sponsors are Janssen Sciences Ireland UC, Janssen Research & Development, LLC, and [disabled in preview].
Summary for JNJ-56136379
| US Patents | 0 |
| International Patents | 17 |
| US Patent Applications | 11 |
| WIPO Patent Applications | 2 |
| Japanese Patent Applications | 2 |
| Clinical Trial Progress | Phase 2 (2019-08-01) |
| Vendors | 18 |
Recent Clinical Trials for JNJ-56136379
| Title | Sponsor | Phase |
|---|---|---|
| A Study of JNJ-56136379 in Healthy Participants | Janssen Research & Development, LLC | Phase 1 |
| A Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Chronic Hepatitis B Virus Infection | Janssen Research & Development, LLC | Phase 2 |
| A Study of JNJ-73763989, JNJ-56136379, Nucleos(t)Ide Analogs, and Pegylated Interferon Alpha-2a in Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection | Janssen Research & Development, LLC | Phase 2 |
Clinical Trial Summary for JNJ-56136379
Top disease conditions for JNJ-56136379
Top clinical trial sponsors for JNJ-56136379
US Patents for JNJ-56136379
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for JNJ-56136379
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| JNJ-56136379 | Australia | AU2017248828 | 2036-04-15 | ⤷ Sign Up |
| JNJ-56136379 | Brazil | BR112018071048 | 2036-04-15 | ⤷ Sign Up |
| JNJ-56136379 | Canada | CA3021068 | 2036-04-15 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
